191 related articles for article (PubMed ID: 33966446)
41. Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome.
Sarak B; Savu A; Kaul P; McAlister FA; Welsh RC; Yan AT; Goodman SG
Circ Cardiovasc Qual Outcomes; 2021 Apr; 14(4):e006646. PubMed ID: 33813856
[TBL] [Abstract][Full Text] [Related]
42. Pharmaceutical payments to physicians may increase prescribing for opioids.
Nguyen TD; Bradford WD; Simon KI
Addiction; 2019 Jun; 114(6):1051-1059. PubMed ID: 30667135
[TBL] [Abstract][Full Text] [Related]
43. Recent advance in lipid management: Focus on PCSK9I (Proprotein Convertase Subtilisin/ Kexin 9 Inhibitors).
Kalra S
J Pak Med Assoc; 2016 Sep; 66(9):1191-1193. PubMed ID: 27654746
[TBL] [Abstract][Full Text] [Related]
44. PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates.
Sammour Y; Dezorzi C; Austin BA; Borkon AM; Everley MP; Fendler TJ; Khumri TM; Lawhorn SL; Nassif ME; Vodnala D; Magalski A; Kao AC; Sperry BW
J Card Fail; 2021 Jul; 27(7):812-815. PubMed ID: 33753241
[TBL] [Abstract][Full Text] [Related]
45. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years.
de Carvalho LSF; Campos AM; Sposito AC
Diabetes Care; 2018 Feb; 41(2):364-367. PubMed ID: 29180351
[TBL] [Abstract][Full Text] [Related]
46. Types and Distribution of Payments From Industry to Physicians in 2015.
Tringale KR; Marshall D; Mackey TK; Connor M; Murphy JD; Hattangadi-Gluth JA
JAMA; 2017 May; 317(17):1774-1784. PubMed ID: 28464140
[TBL] [Abstract][Full Text] [Related]
47. Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017.
Rahman MW; Trivedi NU; Bach PB; Mitchell AP
J Natl Compr Canc Netw; 2021 Dec; 20(13):1-9. PubMed ID: 34965511
[TBL] [Abstract][Full Text] [Related]
48. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
[TBL] [Abstract][Full Text] [Related]
49. Pharmaceutical opioid marketing and physician prescribing behavior.
Beilfuss S; Linde S
Health Econ; 2021 Dec; 30(12):3159-3185. PubMed ID: 34562329
[TBL] [Abstract][Full Text] [Related]
50. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.
Fleischman W; Agrawal S; King M; Venkatesh AK; Krumholz HM; McKee D; Brown D; Ross JS
BMJ; 2016 Aug; 354():i4189. PubMed ID: 27540015
[TBL] [Abstract][Full Text] [Related]
51. A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice.
Knickelbine T; Jia L; White SK; Garberich RF; Oberembt SJ; Wills S; Miedema MD; Brilakis ES
J Clin Lipidol; 2019; 13(2):265-271. PubMed ID: 30745203
[TBL] [Abstract][Full Text] [Related]
52. Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs.
Perlis RH; Perlis CS
PLoS One; 2016; 11(5):e0155474. PubMed ID: 27183221
[TBL] [Abstract][Full Text] [Related]
53. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
[No Abstract] [Full Text] [Related]
54. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.
Duarte-García A; Crowson CS; McCoy RG; Herrin J; Lam V; Putman MS; Ross JS; Matteson EL; Shah ND
Mayo Clin Proc; 2022 Feb; 97(2):250-260. PubMed ID: 35120693
[TBL] [Abstract][Full Text] [Related]
55. Associations Between Industry Payments to Physicians for Antiplatelet Drugs and Utilization of Cardiac Procedures and Stents.
Yanagisawa M; Blumenthal DM; Kato H; Inoue K; Tsugawa Y
J Gen Intern Med; 2022 May; 37(7):1626-1633. PubMed ID: 34378113
[TBL] [Abstract][Full Text] [Related]
56. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and the Risk of Fracture: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Lv F; Cai X; Lin C; Yang W; Hu S; Ji L
Calcif Tissue Int; 2023 Aug; 113(2):175-185. PubMed ID: 37099141
[TBL] [Abstract][Full Text] [Related]
57. Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional Study.
Shen X; DiMario S; Philip K
Adv Ther; 2019 Dec; 36(12):3424-3434. PubMed ID: 31625131
[TBL] [Abstract][Full Text] [Related]
58. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
Morse E; Hanna J; Mehra S
Otolaryngol Head Neck Surg; 2019 Oct; 161(4):605-612. PubMed ID: 31547772
[TBL] [Abstract][Full Text] [Related]
59. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.
Tselmin S; Julius U; Weinert N; Bornstein SR; Schatz U
Atheroscler Suppl; 2019 Dec; 40():38-43. PubMed ID: 31818448
[TBL] [Abstract][Full Text] [Related]
60. Trends in Brand-Name Statin Prescriptions Among Physicians Prescribing Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors From 2016 to 2018.
Yagi R; Inoue K
Endocr Pract; 2021 Sep; 27(9):973-974. PubMed ID: 34126248
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
